PARP Inhibition in Ovarian Cancer Takes Center Stage - prIME Oncology
Clinical Spotlight
Clinical Spotlight

PARP Inhibition in Ovarian Cancer Takes Center Stage

Updates From the 2018 European Oncology Congress in Munich

Not a member of My prIME? Join now for instant access.

Learn about the most current treatment options for ovarian cancer with this expert discussion and related slide deck. This activity features valuable updates and expert perspectives on exciting new developments in PARP inhibition for the management of ovarian cancer released at the 2018 European Oncology Congress in Munich.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides





Release Date

Release Date

Oct 26, 2018

Expiration Date

Oct 26, 2019

Abstract #LBA7_PR: Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial

Abstract #952P: Long-term tolerability of olaparib tablets as maintenance therapy for platinum-sensitive relapsed ovarian cancer (PSR OC): Phase III SOLO2 trial

Abstract #947P: Subgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: effect of prior chemotherapy regimens in ARIEL3

Abstract #944P: QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset

Abstract #936PD: A phase 2 study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa)

  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Jonathan Ledermann, BSc, MD, FRCPUCL Cancer Institute
    London, United Kingdom
  • Kathleen Moore, MDStephenson Cancer Center
    University of Oklahoma
    Oklahoma City, Oklahoma, United States

This educational activity is designed for medical oncologists, gynecologists, and other healthcare providers involved in the management of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify patients with platinum-sensitive ovarian cancer who are appropriate candidates for treatment with PARP inhibitors
  • Describe implementation of data from clinical trials investigating PARP inhibitors in pretreated ovarian cancer into patient care
  • Compare and contrast the tolerability profiles of available PARP inhibitors in ovarian cancer

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.


This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Colombo has disclosed that she has received honoraria for promotional speakers’ bureaus from AstraZeneca, Roche, and Tesaro. She also disclosed membership on advisory committees or review panels for AstraZeneca, Biocad, Clovis, Immunogen, Pfizer, PharmaMar, Roche, Takeda, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ledermann has disclosed that he received grant funding from AstraZeneca. He also disclosed participation on advisory boards for and receipt of lecture fees from AstraZeneca and Clovis Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moore has nothing to disclose in relation to this activity. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.